I. Product Basic Description
This product is a long-acting polypeptide combination injection of Retatrutide 5mg and Cagrilintide 5mg in a fixed ratio. It is a multi-target incretin/amyloid receptor dual-agonist combination formulation specifically developed for metabolic weight management and type 2 diabetes regulation. The two active ingredients are combined at equal doses of 5mg and administered subcutaneously. It features long-acting sustained release and multi-pathway synergistic regulation of metabolism, unlike single GLP-1 weight-loss and blood sugar-lowering peptides. It simultaneously activates three core metabolic receptors, resulting in synergistic effects of fat reduction, blood sugar control, and appetite control.
Physical Mechanism
This combination formulation produces a wide range of metabolic effects by activating multiple complementary hormonal pathways:
Retatrutide (Triple Receptor Agonist): As a synthetic peptide, Retatrutide can simultaneously activate glucagon-like peptide-1 (GLP-1), gastrin-releasing peptide (GIP), and glucagon receptors. This triple action enhances glucose homeostasis, suppresses appetite through central and peripheral pathways, and increases energy expenditure in the liver and adipose tissue pathways.
Cagrilintide (long-acting amylin analog): Cagrilintide is a chemically stable human insulin-like peptide analog that primarily targets the amylin receptor. It further delays gastric emptying, promotes satiety, and reduces calorie intake by activating brain regions that control homeostasis and hedonic eating.
Synergistic effect: The combination of these two peptides simultaneously targets central and peripheral metabolic pathways, influencing multiple satiety centers in the hypothalamus, providing a powerful dual signal for reducing hunger and improving energy balance.
Main functions: In research models, this peptide combination is primarily used in the following areas: Obesity and severe overweight modeling: Significantly reduces body weight and visceral fat in obesity models while helping to protect lean body mass (muscle mass) during weight loss.
Appetite regulation and satiety research: Synergistically suppresses appetite and reduces calorie intake, targeting multiple hypothalamic hunger pathways.
Insulin Resistance and Glycemic Control: Enhances insulin sensitivity and glucose tolerance, delays gastric emptying to improve postprandial glycemic control.
Lipid Metabolism and Fat Oxidation: Improves lipid metabolism and fatty acid oxidation, increasing basal energy expenditure via the glucagon receptor pathway.
Non-Stimulating Weight Regulation Strategy: Explores hypothalamic energy balance signaling and comprehensive weight regulation mechanisms.
Key Features:
Multi-Target Synergistic Effect: Simultaneously activates GLP-1, GIP, glucagon receptor, and amylin receptor, producing broad metabolic effects beyond those of a single GLP-1 analog.
Superior Weight Loss and Body Remodeling Potential: Preclinical data show enhanced effects on satiety, insulin sensitivity, and fat oxidation, achieving significant fat reduction while maximizing muscle mass preservation.
High Purity and Rigorous Manufacturing Standards: The product is manufactured using solid-phase peptide synthesis (SPPS), with purity verified by high-performance liquid chromatography and mass spectrometry (HPLC-MS/MS). It is manufactured in an ISO-certified sterile laboratory environment and supplied as a lyophilized powder for precise reconstitution in research settings.
Cutting-edge scientific research attributes: As an advanced formula in the field of metabolic research, it provides an ideal experimental model tool for exploring complex metabolic dysfunctions.
III. Core Functions and Efficacy
1. Weight and Body Fat Management
Significantly reduces overall weight, prioritizing visceral and abdominal fat reduction;
Continuously reduces BMI, waist circumference, and body fat percentage;
Reduces binge eating and carbohydrate/sweet cravings, naturally reducing daily total calorie intake.
2. Type 2 Diabetes Blood Glucose Regulation
Significantly reduces fasting blood glucose and 2-hour postprandial blood glucose;
Long-term reduction of glycated hemoglobin (HbA1c);
Improves insulin resistance and repairs pancreatic β-cell secretory function;
Reduces large fluctuations in blood glucose and lowers the risk of hypoglycemia.
3. Improvement of Metabolic Syndrome
Reduces triglycerides and low-density lipoprotein (LDL), and increases high-density lipoprotein (HDL);
Assists in lowering systolic and diastolic blood pressure;
Improves fatty liver (non-alcoholic fatty liver disease), reducing hepatic steatosis.
4. Additional Metabolic Benefits
Delays gastric emptying, improving postprandial hunger and frequent snacking; Reduces hunger-induced eating, stabilizing eating rhythms; Maintains long-lasting basal metabolic activity, resulting in less weight rebound after discontinuation compared to single-target GLP-1 formulations.
IV. Key Product Features
Synergistic Multi-Target Effect with Four Receptors
Simultaneously activates four major metabolic receptors: GLP-1, GIP, glucagon, and amylintide. Compared to single-target formulations like semaglutide or telpolide, the synergistic effect on weight loss and blood sugar control is more pronounced.
Golden 5mg Dosage Ratio for Better Tolerability
Retatrutide 5mg + Cagrilintide 5mg balances lipolysis and controls appetite intensity, significantly alleviating severe nausea and vomiting that often occur with high-dose amylintide alone, resulting in mild and manageable gastrointestinal side effects.
Long-Acting Peptide Structure for User-Friendly Dosage Cycle
Both molecules are modified with fatty acid side chains, binding to albumin to prolong their in vivo half-life, supporting low-frequency subcutaneous injections and improving compliance.
Targeted Fat Reduction for Visceral Fat
Unlike ordinary weight loss products that only reduce subcutaneous water, this compound targets and breaks down visceral fat through the glucagon pathway, improving abdominal obesity.
Stable Blood Sugar, Low Risk of Hypoglycemia
Its glucose-dependent insulin secretion mechanism only works when blood sugar is elevated. No additional insulin stimulation is needed in normal/hypoglycemic states, and the incidence of hypoglycemia is even lower when used in combination with hypoglycemic drugs.
Dual Dietary Control Logic, Long-Lasting Satiety
It inhibits hunger through both central (hypothalamus) and peripheral (gastrointestinal) mechanisms, allowing a single feeling of fullness to last 12–24 hours, naturally controlling diet without the need for forced dieting.
Wideer Range of Suitable Individuals
Suitable for individuals with simple obesity/overweight, type 2 diabetes, metabolic syndrome, insulin resistance, and non-alcoholic fatty liver disease.
Rebound Inhibition Advantage
It regulates basal metabolism through multiple pathways, preventing a decrease in basal energy expenditure due to simple calorie restriction. With proper use, the weight maintenance effect after discontinuation is superior to single-target GLP-1 preparations.
Over 10 Years of Export Experience
We have successfully served clients in over 10 countries, ensuring reliable delivery and consistent product quality.
High Purity and Stable Supply
All products are ≥99% pure, laboratory tested, and have stable inventory for long-term supply.
OEM/Small Brand Services Available
Flexible customization options, including labeling, packaging, and formulation support, to help your brand grow.
Global Shipping, Discreet Packaging
Fast, secure, and trackable global shipping-discreet shipping options are available.
Responsive Customer Service
We provide dedicated pre-sales and after-sales support. We offer rapid responses, tracking updates, and long-term partnership support.
Hot Tags: peptide retatrutide 5mg + cagrilintide 5mg 10mg/vial, China peptide retatrutide 5mg + cagrilintide 5mg 10mg/vial manufacturers, suppliers, factory
